US biopharma Alto Neuroscience (NYSE: ANRO) a firm focused on the development of novel precision medicines for neuropsychiatric disorders, has highlighted The Lancet Psychiatry’s publication of data from the PAX-D study evaluating pramipexole in patients with treatment-resistant depression (TRD).
The study was conducted by the University of Oxford and was funded by the UK government’s National Institute for Health and Care Research.
Optimizing tolerability to overcome current barriers may lead to a paradigm shift in treatment
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze